Loading page
Loading page
Loading substance route
Moderate liability among addictive drugs; psychological dependence may occur, particularly when used at high doses or in non-medical contexts. At therapeutic doses prescribed for ADHD treatment, methylphenidate lacks the capacity to cause addiction as it does not sufficiently activate the reward system. Repeated high-dose administration can induce expression of ΔFosB in the nucleus accumbens, a biomolecular mechanism associated with drug addiction.
Displays dependence liability similar to amphetamine. Physical dependence is not prominently described in the literature compared to psychological dependence, consistent with the stimulant class profile.
Overdose is rarely fatal with appropriate care. Severe overdose symptoms include hyperpyrexia, sympathomimetic toxidrome, convulsions, rhabdomyolysis, coma, and circulatory collapse. Treatment typically involves benzodiazepines, with antipsychotics and α-adrenoceptor agonists as second-line therapies.
Sudden death has been reported in patients with pre-existing cardiac structural abnormalities, arrhythmias, coronary disease, or other cardiac conditions; however, FDA-commissioned studies in 2011 found no association between serious cardiovascular events and medical use of methylphenidate in otherwise healthy individuals.
Liver toxicity is extremely rare with therapeutic use; animal studies in B6C3F1 mice, which are particularly sensitive to hepatic tumors, showed hepatoblastoma development at twice the maximum recommended human dose.
Can increase intraocular pressure due to pupil dilation, which may cause further optic nerve damage in patients with pre-existing glaucoma; occasional users without glaucoma face minimal risk.
Prolonged treatment in children may cause mild reductions in height, estimated at approximately 1 cm or less per year during the first three years, with a cumulative decrease of about 3 cm over 10 years of use.
Considered unlikely to be carcinogenic based on available evidence. Not mutagenic but weakly clastogenic in Chinese Hamster Ovary cells. Hepatoblastomas observed only in B6C3F1 mice, a strain particularly sensitive to hepatic tumor development, at doses twice the maximum recommended human dose.
Can worsen psychosis in individuals who are already psychotic, and in very rare cases has been associated with the emergence of new psychotic symptoms. Should be used with extreme caution in people with bipolar disorder due to potential induction of mania or hypomania. Visual hallucinations are very rarely reported.
Seizures are listed among serious but uncommon side effects. Convulsions may occur in severe overdose situations involving sympathomimetic toxidrome.
Dexmethylphenidate is the dextrorotatory enantiomer of methylphenidate, isolated and developed as a separate pharmaceutical product. It received approval for medical use in the United States in 2001 and was subsequently introduced to the market in 2002 under the brand name Focalin. The rationale…
Marketed as a prescription product under the brand name Focalin since November 2001. Generic formulations (Dexmethylphenidate HCl) are also available from multiple pharmaceutical manufacturers including Sandoz and Adare Pharmaceuticals.